2025 BCHIM: Poclight CRET Measurement Empowers Platelet Activation Function Testing

October 17-18, 2025 · Beijing Huanghe Jingdu Conference Center

The 4th Thrombosis and Hemostasis Integrative Medicine Conference, organized by the Thrombosis and Hemostasis Branch of the Beijing Society of Integrative Medicine, was successfully held on October 17-18, 2025, at the Beijing Huanghe Jingdu Conference Center.

The event brought together leading experts and scholars from medical institutions and research organizations across China. Participants engaged in in-depth discussions on cutting-edge biomedical technologies, advances in thrombosis and hemostasis research, and multidisciplinary approaches to clinical practice.

During the session “Research Progress on Tumor-Related Hemostatic Abnormalities,” speakers shared the latest research findings and highlighted the role of CRET Measurement in advancing platelet activation studies. The experimental results obtained using CRET were found to be highly consistent with real-world clinical outcomes, underscoring its research and diagnostic value.

2.  CRET Measurement : A Breakthrough in Platelet Activation Testing

Poclight Biotech’s CRET Technology enables precise detection of cellular markers, including platelet CD series (for platelet activation analysis). It represents the world’s first rapid, portable, room-temperature-stable, and cost-efficient platform for platelet activation testing with simple operation and robust performance.

The technology supports testing of markers such as CD41, CD61, CD42a, CD42b, CD45, CD62p, PAC-1, AA, and ADP, among others. By integrating immunological and molecular innovations, CRET overcomes the limitations of traditional flow cytometry, making platelet activation and function testing more accessible and practical in clinical settings.

3.  Our Commitment

Poclight Biotech remains committed to working closely with industry experts to advance the comprehensive management of platelet-related disorders - from early risk screening and accurate diagnosis to therapeutic monitoring and prognosis assessment.

Together, we aim to enhance the diagnostic and treatment capabilities for thrombotic diseases and elevate the overall quality of medical services.

To learn more about Poclight's CRET 5-generation chemiluminescence immunoassay and platelet activation function testing solutions, please contact us.